Does the media prefer BEAM or EDIT?

In the previous week, Beam Therapeutics had 6 more articles in the media than Editas Medicine. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.93 beat Beam Therapeutics' score of 0.73 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for CRISPR Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.64 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COLL or EDIT?

In the previous week, Collegium Pharmaceutical and Collegium Pharmaceutical both had 2 articles in the media. Collegium Pharmaceutical's average media sentiment score of 0.96 beat Editas Medicine's score of 0.93 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or CGEM?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.60 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Editas Medicine (EDIT) Competitors

$3.20 +0.35 (+12.28%)

Closing price 04:00 PM Eastern

Extended Trading

$3.16 -0.05 (-1.41%)

As of 07:25 PM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, COLL, and CGEM

Should you buy Editas Medicine stock or one of its competitors? MarketBeat compares Editas Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Editas Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Beam Therapeutics had 6 more articles in the media than Editas Medicine. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.93 beat Beam Therapeutics' score of 0.73 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$164.01M	21.92	-$79.99M	-$0.68	N/A
Editas Medicine	$38.69M	8.10	-$160.06M	-$1.23	N/A

Beam Therapeutics presently has a consensus price target of $46.83, indicating a potential upside of 34.00%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 68.75%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Editas Medicine	-281.59%	-677.39%	-58.25%

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for CRISPR Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.64 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$1M	5,434.90	-$581.60M	-$6.22	N/A
Editas Medicine	$38.69M	8.10	-$160.06M	-$1.23	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus target price of $67.78, indicating a potential upside of 20.28%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 68.75%. Given Editas Medicine's higher possible upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Editas Medicine had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 2 mentions for Editas Medicine and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.89 beat Editas Medicine's score of 0.93 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Editas Medicine	Positive
Intellia Therapeutics	Very Positive

Editas Medicine currently has a consensus price target of $5.40, indicating a potential upside of 68.75%. Intellia Therapeutics has a consensus price target of $20.46, indicating a potential upside of 23.16%. Given Editas Medicine's stronger consensus rating and higher probable upside, research analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$38.69M	8.10	-$160.06M	-$1.23	N/A
Intellia Therapeutics	$66.09M	35.11	-$412.69M	-$3.54	N/A

Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

71.9% of Editas Medicine shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Collegium Pharmaceutical and Collegium Pharmaceutical both had 2 articles in the media. Collegium Pharmaceutical's average media sentiment score of 0.96 beat Editas Medicine's score of 0.93 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Collegium Pharmaceutical presently has a consensus price target of $57.50, indicating a potential upside of 59.81%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 68.75%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Collegium Pharmaceutical has a net margin of 9.41% compared to Editas Medicine's net margin of -281.59%. Collegium Pharmaceutical's return on equity of 95.18% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

Collegium Pharmaceutical has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.47	$62.87M	$2.04	17.64
Editas Medicine	$38.69M	8.10	-$160.06M	-$1.23	N/A

Summary

Collegium Pharmaceutical beats Editas Medicine on 10 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Cullinan Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Editas Medicine currently has a consensus price target of $5.40, indicating a potential upside of 68.75%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 73.72%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Editas Medicine has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$38.69M	8.10	-$160.06M	-$1.23	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.60 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Cullinan Therapeutics' return on equity of -51.45% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cullinan Therapeutics beats Editas Medicine on 9 of the 15 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$313.30M	$3.65B	$6.84B	$12.43B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-2.60	21.29	25.83	24.36
Price / Sales	8.10	195.79	511.51	84.16
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	11.43	8.71	10.98	6.49
Net Income	-$160.06M	$23.87M	$3.57B	$336.61M
7 Day Performance	14.29%	4.23%	3.06%	0.90%
1 Month Performance	-7.51%	1.71%	0.72%	-0.36%
1 Year Performance	40.35%	69.92%	36.82%	31.26%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	2.6586 of 5 stars	$3.20 +12.3%	$5.40 +68.8%	+25.0%	$313.30M	$38.69M	N/A	230
BEAM Beam Therapeutics	2.2019 of 5 stars	$33.20 -6.6%	$46.83 +41.1%	+107.2%	$3.66B	$139.74M	N/A	510	Insider Trade
CRSP CRISPR Therapeutics	2.3299 of 5 stars	$53.99 -0.7%	$67.78 +25.5%	+15.6%	$5.24B	$3.51M	N/A	460	Analyst Upgrade
NTLA Intellia Therapeutics	2.7829 of 5 stars	$15.25 -3.2%	$20.46 +34.1%	+74.5%	$2.20B	$67.67M	N/A	600
COLL Collegium Pharmaceutical	2.654 of 5 stars	$34.62 +3.5%	$57.50 +66.1%	+22.3%	$1.08B	$780.57M	16.97	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, COLL, and CGEM

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Collegium Pharmaceutical?

Summary

How does Editas Medicine compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, COLL, and CGEM

How does Editas Medicine compare to Beam Therapeutics?

Does the media prefer BEAM or EDIT?

Do insiders & institutionals believe in BEAM or EDIT?

Which has more volatility and risk, BEAM or EDIT?

Which has better earnings and valuation, BEAM or EDIT?

Do analysts recommend BEAM or EDIT?

Is BEAM or EDIT more profitable?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Is CRSP or EDIT more profitable?

Does the media refer more to CRSP or EDIT?

Which has stronger valuation and earnings, CRSP or EDIT?

Do institutionals and insiders have more ownership in CRSP or EDIT?

Which has more volatility & risk, CRSP or EDIT?

Do analysts rate CRSP or EDIT?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Is EDIT or NTLA more profitable?

Do institutionals & insiders believe in EDIT or NTLA?

Does the media prefer EDIT or NTLA?

Do analysts recommend EDIT or NTLA?

Which has stronger earnings & valuation, EDIT or NTLA?

Which has more volatility and risk, EDIT or NTLA?

Summary

How does Editas Medicine compare to Collegium Pharmaceutical?

Do insiders and institutionals believe in COLL or EDIT?

Does the media favor COLL or EDIT?

Which has more risk and volatility, COLL or EDIT?

Do analysts rate COLL or EDIT?

Is COLL or EDIT more profitable?

Which has preferable valuation & earnings, COLL or EDIT?

Summary

How does Editas Medicine compare to Cullinan Therapeutics?

Do analysts prefer EDIT or CGEM?

Which has more volatility and risk, EDIT or CGEM?

Which has stronger valuation & earnings, EDIT or CGEM?

Does the media favor EDIT or CGEM?

Is EDIT or CGEM more profitable?

Do insiders and institutionals believe in EDIT or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools